Skip to main content
. 2012 Mar;26(3):1027–1039. doi: 10.1096/fj.11-195321

Figure 3.

Figure 3.

HIF-1α inhibition decreases expression of VEGF-A and VEGF-C. A) Relative expression of VEGF-A or VEGF-C mRNA in the 1-cm region centered at the wound (boxed area) after treatment with YC-1 or control 3 wk after surgery (fold change relative to control). B) ELISA for local VEGF-C expression following YC-1 treatment for 3 wk (pg/ml). C) Western blot for VEGF-A and VEGF-C following treatment with YC-1, 2ME, or respective controls at 3 wk after surgery (fold change relative to controls). D, E) Number of VEGF-A+ (D) and VEGF-C+ (E) cells per high-power field in the 5-mm region distal to the wound following HIF-1α inhibition or control treatment for 3 wk. High-power photomicrographs (×40) of immunohistochemical staining for VEGF-A (D) and VEGF-C (E) are shown. F) Numbers of LYVE-1/VEGF-C double-positive cells, determined by immunohistochemical colocalization, in the region 5-mm distal to the wound. G) High-power photomicrographs of LYVE-1 and VEGF-C colocalization. Red, LYVE-1; green, VEGF-C. H) VEGF-C expression (pg/ml) by ELISA in draining lymph nodes following YC-1 or vehicle control treatment in animals administered CFA-OVA. I, J) Left panels: number of VEGF-A+ (I) or VEGF-C+ (J) cells per high-power field in draining lymph nodes following treatment with YC-1, 2ME, or respective controls after CFA-OVA injection. Right panels: high-power photomicrographs (×40) for VEGF-A (I) and VEGF-C (J) within inflamed draining lymph nodes. Scale bars = 50 μm (D, E); 40 μm (G); 100 μm (I, J). *P < 0.05, **P < 0.01, ***P < 0.001.